Article

J&J Opens Doxil Rationing Program To New Patients

Johnson & Johnson (JNJ) will begin allowing new patients to enroll in a rationing program to receive the cancer drug Doxil because some of the limited, remaining supply has been freed up.

In a notice posted on the Doxil website Wednesday, J&J said it will reopen enrollment in the program starting Friday because some prior requests from doctors have changed and freed up supplies. Some doctors told J&J that Doxil supplies earmarked for patients already enrolled were no longer needed or they opted patients out of the program, the company said.

About 1,000 patients are now receiving Doxil--which treats ovarian and other cancers--through an allocation program that J&J created last year to address a product shortage.

Read the full story: http://hcp.lv/K6a9Bp

Source: Morningstar

Related Videos
Lawrence Eichenfield, MD, FAAD
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Michelle Hessen, OD
Douglas Flora, MD, FACCC
Molly Dean, MSW, Siftwell
Dr Xin Hu
Bridgette J. Picou, LVN, ACLPN, The Well Project
Priscilla Tsondai, MD, MPH, IAS/CIPHER
Mia Moore, PhD, Fred Hutch Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo